Cost-effectiveness analysis of tofacitinib for the treatment of moderate to severe rheumatoid arthritis: a systematic review and meta-analysis.

导出 LinkOut

翻译打印收藏纠错

第一作者： Behzad,Fatemi

第一单位： Pharmaceutical Management and Economics Research Center (PMERC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.

作者： Behzad,Fatemi ^[1] ; Neda,Yaghoubi ^[2] ; Nikta,Shobeiri ^[3] ; Razieh,Ahmadi ^[2] ; Taraneh,Mousavi ^[4] ; Fatemeh,Soleymani ^[5] ; Soheila,Rezaei ^[2]

作者单位： Pharmaceutical Management and Economics Research Center (PMERC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran. ^[1] Department of Pharmacoeconomics and Pharma Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ^[2] Department of Pharmaceutical Control, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. ^[3] Toxicology & Diseases Group, Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.;Department of Toxicology & Pharmacology, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. ^[4] Pharmaceutical Management and Economics Research Center (PMERC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.;Department of Pharmacoeconomics and Pharmaceutical Management, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. ^[5]

关键词 Tofacitinib incremental cost-effectiveness ratio meta-analysis net monetary benefit quality-adjusted life years rheumatoid arthritis